Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 209.02

+3.2%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert L. Ray who wrote (22834)	6/29/1998 2:15:00 PM
From: Henry Niman	Read Replies (2) of 32384

Panretin gel is for KS and the incidence is decline with the widespread use of PIs. However, the decline may be temporary as the number of patients failing PI's continues to increase as does the prevalence of resistant viruses. Panretin topical's target population (KS) is somewhat larger than Targretin topical (CTCL), but off label use is expected for both topical formulations as well as the oral formulas. Targretin has shown efficacy for breast cancer and metabolic diseases in animal models and the number of clinical indications is also higher for Targretin than Panretin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next